'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Saurav VermaDaniel A BreadnerJacques RaphaelPublished in: Current oncology (Toronto, Ont.) (2023)
Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for several hematological and solid malignancies, including breast, urothelial and gastric carcinoma. Recently, trastuzumab deruxtecan (TDXd) was the first ADC approved for previously treated metastatic HER2-mutant non-small cell lung cancer (NSCLC). Many promising ADCs are in the pipeline for clinical development in non-small cell lung cancer, including sacituzumab govitecan, patritumab deruxtecan, datopotamab deruxtecan and tusamitamab ravtansine. There is a hope that these drugs would cater to the unmet need of specific patient populations, including patients with currently untargetable mutations. We hope these drugs, e.g., TROP2 targeted ADCs, will also give more options for therapy in NSCLC to improve outcomes for patients. In this comprehensive review, we will be discussing the recent evidence including targets, efficacy and the safety of newer ADC candidates in NSCLC. We will also briefly discuss the specific toxicities, novel biomarkers, overcoming resistance mechanisms, challenges and the way forward, as these new ADCs and combinations find a way into the clinical practice.
Keyphrases
- small cell lung cancer
- cancer therapy
- clinical practice
- advanced non small cell lung cancer
- newly diagnosed
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- drug induced
- magnetic resonance imaging
- chronic kidney disease
- metabolic syndrome
- dendritic cells
- diffusion weighted imaging
- prognostic factors
- epidermal growth factor receptor
- drug delivery
- artificial intelligence
- big data
- high grade
- stem cells
- brain metastases
- skeletal muscle
- case report
- cell therapy
- drug administration